A small-molecule fusion inhibitor of influenza virus is orally active in mice
-
- Maria J. P. van Dongen
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Rameshwar U. Kadam
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
-
- Jarek Juraszek
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Edward Lawson
- Discovery Sciences, Janssen Research & Development, 1400 McKean Rd., Spring House, PA, USA.
-
- Boerries Brandenburg
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Frederike Schmitz
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Wim B. G. Schepens
- Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
-
- Bart Stoops
- Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
-
- Harry A. van Diepen
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Mandy Jongeneelen
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Chan Tang
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Jan Vermond
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Alida van Eijgen-Obregoso Real
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Sven Blokland
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Divita Garg
- Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
-
- Wenli Yu
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
-
- Wouter Goutier
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Ellen Lanckacker
- Janssen Infectious Diseases and Vaccines, Janssen Research & Discovery, Turnhoutseweg 30, Beerse, Belgium.
-
- Jaco M. Klap
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Daniëlle C. G. Peeters
- Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
-
- Jin Wu
- Janssen Infectious Diseases and Vaccines, Janssen Research & Discovery, Turnhoutseweg 30, Beerse, Belgium.
-
- Christophe Buyck
- Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
-
- Tim H. M. Jonckers
- Janssen Infectious Diseases and Vaccines, Janssen Research & Discovery, Turnhoutseweg 30, Beerse, Belgium.
-
- Dirk Roymans
- Janssen Infectious Diseases and Vaccines, Janssen Research & Discovery, Turnhoutseweg 30, Beerse, Belgium.
-
- Peter Roevens
- Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
-
- Ronald Vogels
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Wouter Koudstaal
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Robert H. E. Friesen
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Pierre Raboisson
- Janssen Infectious Diseases and Vaccines, Janssen Research & Discovery, Turnhoutseweg 30, Beerse, Belgium.
-
- Dashyant Dhanak
- Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
-
- Jaap Goudsmit
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.
-
- Ian A. Wilson
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
説明
<jats:title>A small molecule that targets influenza</jats:title> <jats:p> Many of us rely on seasonal vaccines for protection against influenza and are only too aware of their limited breadth. Broadly neutralizing antibodies (bnAbs) that target the conserved hemagglutinin (HA) stem of the influenza virus provide hope for the development of universal vaccines and are being evaluated in clinical trials. Van Dongen <jats:italic>et al.</jats:italic> selected and optimized a small-molecule lead compound that recapitulates key interactions of the bnAb with HA. Like the bnAb, the compound inhibited viral fusion in the endosomes of target cells. The compound protected mice from influenza after oral administration and neutralized virus infection in a 3D cell culture of human bronchial epithelial cells. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , this issue p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" related-article-type="in-this-issue" xlink:href="10.1126/science.aar6221">eaar6221</jats:related-article> </jats:p>
収録刊行物
-
- Science
-
Science 363 (6431), 2019-03-08
American Association for the Advancement of Science (AAAS)
